Immunotherapy after liver transplantation: Where are we now?

Table 3 Descriptive characteristics of patients with immunotherapy for post-transplant hepatocellular carcinoma recurrence

	All	Nivolumab	Pembrolizumab	P value
Total (%)	19	14 (74)	5 (26)
Rejection (%)	6 (32)	5 (36)	1 (20)	0.52
Early mortality (%)	5 (26)	5 (36)	0 (0)	0.12
Line of systemic therapy	2 (1-3)	3 (2-4)	2 (1-2)	0.03
Tumour PD-L1 positivity (%)	3/7 (43)	3/7 (43)	0/0 (-)
Best treatment response (%)
Complete response	2 (11)	0 (0)	2 (40)	0.03
Partial response	0 (0)	0 (0)	0 (0)	0.64
Stable disease	2 (11)	1 (7)	1 (20)	0.58
Progressive disease	8 (42)	7 (50)	1 (20)	0.03
Progression-free survival	2.5 ± 1.0	1.3 ± 1.1	12.4	0.004
Overall survival	7.3 ± 2.7	4.0 ± 3.4	19.2	0.006

PD-L1: Programmed death ligand-1.